問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱宗傑

Recruiting

List

24Cases

2025-11-01 - 2033-12-31

Phase III

Not yet recruiting
A phase III, open-label, randomized, multicenter, parallel-group trial evaluating the efficacy and safety of first-line trastuzumab deruxtecan combined with rilvegostomig or volrustomig versus pembrolizumab plus chemotherapy in locally advanced, unresectable, or metastatic HER2-overexpressing non-squamous NSCLC (DESTINY-Lung07).

  • Condition/Disease

    Locally advanced unresectable or metastatic HER2-overexpressing non-squamous non-small cell lung cancer

  • Test Drug

    Trastuzumab Deruxtecan(AZD4552 DS-8201A)

Participate Sites
9Sites

Recruiting9Sites

2025-11-19 - 2030-06-30

Phase II

Not yet recruiting
A phase 2 open-label trial of navicixizumab monotherapy in patients with platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

  • Condition/Disease

    Platinum-based therapy-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer

  • Test Drug

    Navicixizumab

Participate Sites
10Sites

Recruiting10Sites

2025-03-01 - 2029-03-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

2018-10-30 - 2022-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2018-09-26 - 2022-05-18

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting6Sites

蘇柏榮
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2024-01-01 - 2030-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2018-09-28 - 2030-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting7Sites

2013-08-12 - 2026-08-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2017-10-01 - 2024-11-07

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2019-06-01 - 2024-07-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB